Transfuse Neonates with Cord Blood-Derived Red Blood Cells: A Feasibility Study to Assess Allogeneic Cord Blood Unit Fractionation and Validation

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 275-275 ◽  
Author(s):  
Maria Bianchi ◽  
Luciana Teofili ◽  
Carmen Giannantonio ◽  
Alessandra Landini ◽  
Patrizia Papacci ◽  
...  

Abstract Abstract 275 Newborns are currently transfused with RBCs from adults, which mainly contain adult hemoglobin (HbA). HbA has a lower affinity for oxygen than fetal hemoglobin: therefore adult red cell transfusion could be responsible for increased oxygen increasing the risk of the “oxygen radicals disease of the newborn”. Autologous umbilical cord blood has been suggested as the only alternative source of blood for newborn transfusions. Previous studies, however, demonstrated that autologous cord blood transfusions in newborns are not sufficient to entirely cover the early neonatal blood requests. We reported the preliminary results of our study carried out to assess the feasibility of an allogeneic cord blood (ACB) transfusion program for prematures in terms of preparation and yield of valid ACB red blood cell (RBC) units. ACB units collected at the Cord Blood Bank but not suitable for processing and storage for allogeneic transplant cord blood were evaluated. Eligible criteria for cord blood collection were: more than 37 weeks of gestation, absence of mother's infection or fever 24 hours before the delivery, no stain of the amniotic fluid. ACB units eligible for our study contained more than 60 mL of cord blood, with no clots or hemolysis. We prepared buffy coat–depleted ACB RC units by automated separation (Compomat G4®, Fresenius HemoCare, Germany) in a processing set (Compoflex®). Suspension in SAG-mannitol and post-storage filtration was performed to obtain a leukocyte-depleted red cell unit. Resuspended units were stored for fourteen days after manipulation (2–6°C). Cultures for bacterial contamination were performed immediately after manipulation and after 14 days; biochemical determination (LDH, glucose, lactate, potassium, chloride, sodium, pH and pO2) were performed the day of fractionation (=0) and after 7 and 14 days of storage. Biochemical data were also compared to the same parameters obtained from adult red blood cell concentrates. We collected 76 ACB units. Thirty-three were discharged for insufficient volume or clots. The median collection volume of the 43 remaining units was 92.3 (± 18.3) ml. After fractionation, 43 ACB RC units were obtained with a median volume of 31.2 (± 8.2) ml and a median hematocrit of 59 ± 2%. Microbial contamination was absent in all units after manipulation and after 14 days; viral tests carried out on mother's blood at the time of cord blood collection were negative. Biochemical parameters maintained rather well up to 14 days of storage, but less resistant than adult red cells. Our data highlight that ACB is a promising source of RBC for transfusion in preterm infants. Besides the reduction of waste of not validated ACB units collected in the Cord Blood Bank, transfusional utilization of ACB RBC can overcome several problems of autologous cord blood transfusion: insufficient volumes is less frequent in ACB from term newborns and the incidence of clots, which is one of the more frequent cause of ineligibility of cord blood units, is substantially reduced when collection is performed by trained staff, in term neonates and using adequate blood shakers. Microbial contamination is prevented by adopting the strict eligibility criteria and the adequate aseptic collection technique adopted in the Cord Blood Bank. In conclusion, the preparation of transfusionally valid RCs from ACB is possible and convenient. Clinical studies are needed to evaluate the efficacy and safety of this new transfusion practice. Disclosures: No relevant conflicts of interest to declare.

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 5441-5441
Author(s):  
Jon Walker ◽  
Geralyn Annett ◽  
Karen O'Donnell ◽  
Christine C. Posey ◽  
Delia Roberts ◽  
...  

Abstract California’s Umbilical Cord Blood Collection Program (UCBCP) is a unique, state-funded system designed to capture the diverse HLA profiles of its residents’ umbilical cord blood units (CBUs) for public banking and use in unrelated transplants, while providing a source of high quality cord blood units for qualified researchers. The legislation’s unifying directive to create a sustainable program to collect diverse California CBUs for banking and research guided the development of tools useful for the assessment of potential cord blood collection sites and partner cord blood banks. Here, we present the methodology utilized to develop the UCBCP network of collection sites and partner cord blood banks, and describe mechanisms for sustainability. The process of contract negotiations between the UCBCP, host hospital and partner cord blood bank (CBB) is preceded by identification and analysis of each party, with an emphasis on parameters that are directly related to the intent of the legislation. The Collection Site Assessment Tool evaluates hospitals based on, but not limited to the following criteria; birth rate, ethnic/racial diversity of patient population, proximity to partner cord blood bank, shipping logistics, shipping costs, preferred collection model, and space availability. Data are collected from the CA Dept. of Public Health and hospital staff. Our CBB Assessment Tool was developed as a scoring mechanism to evaluate proposals from cord blood banks wishing to be qualified to receive California’s CBUs. Parameters considered include CBB licensure by the FDA, collection model, capacity, experience and CBB financials. By tailoring negotiations and contracts based on results from the assessment tools, each partnership between collection site and cord blood bank is uniquely suited to the needs of each party and promotes the UCBCP mission, which ultimately serves the patients who receive the transplants. This approach requires effort, creativity and transparency up front as term lists are created and negotiated, and success is dependent on reaching a consensus between hospital administrators, Labor and Delivery staff, CBB officials and the UCBCP, prior to contract signing. The number of contracts uniting hospital, CBB and the UCBCP range from 1-3, depending on the requirements of each party. UCBCP sustainability issues are covered under contracts between the CBB and the UCBCP, such as disbursement of CBUs that do not meet public banking criteria to researchers or fees paid to the UCBCP upon retrieval of a UCBCP-funded CBU for transplant. Distribution of high-quality CBUs for research is an important aspect of the legislation that also supports the UCBCP sustainability funding plan and is non-negotiable, although the UCBCP does provide funding and support for these activities. Our research-grade CBUs are provided fresh and are not manipulated, with an average volume of 94 mL and an average total nucleated cell count of 8.7 x 108. Our standards for research-grade CBUs are high to encourage the use of cord blood stem and progenitor cells in basic and pre-clinical studies, which also ultimately serves the transplant patient community. The flexible model the UCBCP has developed to increase cord blood collections in California can serve as a template for other states and collection programs. Disclosures: No relevant conflicts of interest to declare.


2018 ◽  
Vol 7 ◽  
pp. S26-S26
Author(s):  
Karen Mostert ◽  
Michael Halpenny ◽  
Daniel Bartlett ◽  
Todd Campbell ◽  
Nicholas Dibdin ◽  
...  

Transfusion ◽  
2017 ◽  
Vol 57 (9) ◽  
pp. 2225-2233 ◽  
Author(s):  
Diana Vanegas ◽  
Lady Triviño ◽  
Cristian Galindo ◽  
Leidy Franco ◽  
Gustavo Salguero ◽  
...  

Author(s):  
Chu Thi Thao ◽  
Nguyen Van Tinh ◽  
Le Cong Luc ◽  
Luong Thi Thanh Ha ◽  
Tran Van Phuc ◽  
...  

The umbilical cord blood (CB) has recently been considered an abundant source of hematopoietic stem cells (HSCs) for transplantation compared to bone marrow. However, the collection and processing of CB have a high risk of microbial contamination. Hence, the procedures to collect and process the UCB are carefully considered. This study evaluates the microbial contamination rate to find the frequency and distribution of bacterial organisms among CB sampling and processing in Vietnam. In addition, this study correlates with contamination rates between the delivery method, cesarean section, and vaginal delivery. The results create best practices to avoid a high level of contamination of UCB during collection and processing for biobanking.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3645-3645
Author(s):  
Elizabeth J. Shpall ◽  
Safa Karandish ◽  
Tara Sadeghi ◽  
Chitra Hosing ◽  
Christopher J. Garcia ◽  
...  

Abstract Cord blood (CB) cells are being used increasingly as a source of hematopoietic support in patients lacking human leukocyte antigent (HLA)-matched family or unrelated donors. 1124 CB units were collected, based on obstetrician preference, with the placenta either in utero or ex utero. If logistically feasible, both an in utero collection followed immediately by an additional ex utero collection once the placenta was delivered was performed. We compared the distribution of the collection parameters shown in the following table, using non-parametric tests [data expressed as median (range)]: Athough the volume of CB collected was highest with the sequential in utero plus ex utero method, the number of total nucleated cells (TNCs) and CD34+ cells was similar for both the in utero procedures and higher than with the ex utero alone procedure. The number of CB units that had microbial contamination was similar for all three groups: ex utero-0 CB units, in utero-1 CB unit and in utero plus ex utero-1 CB unit. There were no clinical adverse events associated with any of the collection procedures. Conclusion: In utero collections are safe and result in CB units with significantly higher volumes, TNCs and CD34+ cells than ex utero collections, with no difference in the microbial contamination rate. CB Parameters Ex Utero (N=390) In Utero (N=334) In+Ex Utero (N=400) In+Ex vs Ex (p) In+Ex vs In (p) In vs Ex (p) Volume (ml) 76.5 88.5 94 <0.0001 0.03 <0.001 (35–199) (45–185) (42–207) Tot Nucleated cells (xE7) 94 115 119 <0.001 0.4 <0.001 (20–267) (36–399) (41–393) CD34+cells (xE6) 2.9 3.4 3.1 0.2 0.16 0.01 (0–30) (0–34) (0–55)


Transfusion ◽  
2020 ◽  
Vol 60 (3) ◽  
pp. 588-597 ◽  
Author(s):  
Paloma Casteleiro Costa ◽  
Patrick Ledwig ◽  
Austin Bergquist ◽  
Joanne Kurtzberg ◽  
Francisco E. Robles

Transfusion ◽  
2003 ◽  
Vol 43 (8) ◽  
pp. 1174-1176 ◽  
Author(s):  
Pilar Solves ◽  
Rosa Moraga ◽  
Vicente Mirabet ◽  
Luis Larrea ◽  
Ma Angeles Soler

Sign in / Sign up

Export Citation Format

Share Document